Loading clinical trials...
Loading clinical trials...
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)
Conditions
Interventions
AZD9793 Intravenous (IV) monotherapy
AZD9793 Subcutaneous (SC) monotherapy
Locations
20
United States
Research Site
La Jolla, California, United States
Research Site
Los Angeles, California, United States
Research Site
Baltimore, Maryland, United States
Research Site
St Louis, Missouri, United States
Research Site
Hackensack, New Jersey, United States
Research Site
Houston, Texas, United States
Start Date
March 27, 2025
Primary Completion Date
February 25, 2028
Completion Date
July 25, 2028
Last Updated
April 6, 2026
NCT07175441
NCT05969860
NCT06427941
NCT05842174
NCT07164313
NCT07118202
AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479information.center@astrazeneca.comLead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions